Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center

Articles by Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center

Final Thoughts on the Management of mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Additional Emerging Therapies for Progressive mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Emerging Agents for Progressive mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Sequencing After Frontline I/O Based Regimen for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Clinical Trials for Relapsed/Refractory mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Upcoming Combination Trials for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

I/O Therapy After Progression on I/O for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Role of TKI After Progression on I/O for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Review of the COSMIC 021 Study for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Introduction and Review of CheckMate 9ER for Metastatic RCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Latest Updated Articles

Role of TKI After Progression on I/O for mRCC
October 23rd 2020
Emerging Agents for Progressive mRCC
October 23rd 2020
Review of the COSMIC 021 Study for mRCC
October 23rd 2020
I/O Therapy After Progression on I/O for mRCC
October 23rd 2020
Introduction and Review of CheckMate 9ER for Metastatic RCC
October 23rd 2020
$Clinical Trials for Relapsed/Refractory mRCC$
Clinical Trials for Relapsed/Refractory mRCC
October 23rd 2020

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma